Teachers Advisors LLC raised its position in Haemonetics Co. (NYSE:HAE) by 1.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,649 shares of the medical instruments supplier’s stock after acquiring an additional 1,039 shares during the quarter. Teachers Advisors LLC owned approximately 0.18% of Haemonetics worth $5,555,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its position in Haemonetics by 3.5% in the 4th quarter. BlackRock Inc. now owns 6,670,988 shares of the medical instruments supplier’s stock valued at $387,452,000 after acquiring an additional 225,160 shares in the last quarter. Victory Capital Management Inc. grew its position in Haemonetics by 0.6% in the 4th quarter. Victory Capital Management Inc. now owns 2,428,236 shares of the medical instruments supplier’s stock valued at $141,032,000 after acquiring an additional 13,710 shares in the last quarter. Neuberger Berman Group LLC grew its position in Haemonetics by 10.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 2,053,458 shares of the medical instruments supplier’s stock valued at $92,139,000 after acquiring an additional 189,797 shares in the last quarter. Renaissance Technologies LLC grew its position in Haemonetics by 11.5% in the 4th quarter. Renaissance Technologies LLC now owns 977,100 shares of the medical instruments supplier’s stock valued at $56,750,000 after acquiring an additional 100,893 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in Haemonetics by 3.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 589,379 shares of the medical instruments supplier’s stock valued at $26,446,000 after acquiring an additional 20,925 shares in the last quarter.
Several equities analysts have weighed in on HAE shares. ValuEngine raised Haemonetics from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $78.00 target price for the company in a research report on Friday, February 9th. Jefferies Group lifted their target price on Haemonetics from $18.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, January 8th. TheStreet downgraded Haemonetics from a “b” rating to a “c+” rating in a research report on Tuesday, February 6th. Finally, Raymond James Financial raised Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $71.33.
Shares of Haemonetics stock opened at $71.53 on Monday. Haemonetics Co. has a one year low of $38.47 and a one year high of $75.45. The stock has a market cap of $3,823.10, a PE ratio of 39.30, a P/E/G ratio of 3.09 and a beta of 0.89. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.82 and a quick ratio of 1.33.
Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.18. Haemonetics had a positive return on equity of 12.39% and a negative net margin of 1.94%. The business had revenue of $234.04 million during the quarter, compared to the consensus estimate of $227.79 million. During the same period in the previous year, the company posted $0.43 earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. sell-side analysts predict that Haemonetics Co. will post 1.86 earnings per share for the current year.
Haemonetics announced that its board has authorized a stock repurchase program on Tuesday, February 6th that allows the company to buyback $260.00 million in shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3343174/teachers-advisors-llc-grows-holdings-in-haemonetics-co-hae.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.